Patents by Inventor Chris YONAN

Chris YONAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BUFFERED FORMULATIONS OF BEVACIZUMAB FOR USE OF TREATING DISEASES
    Publication number: 20210230261
    Abstract: The invention provides buffered aqueous formulations of bevacizumab. The invention further provides methods of making buffered formulations of bevacizumab. The invention provides methods of treating eye disorders, particularly wet age-related macular degeneration and macular edema by administering the buffered antibody compositions of the disclosure.
    Type: Application
    Filed: April 17, 2019
    Publication date: July 29, 2021
    Inventors: Chris YONAN, Wiphusanee DENDAMRONGVIT, Martha HEALY-FRIED
  • Modulation of charge variants in a monoclonal antibody composition
    Patent number: 10696735
    Abstract: Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to a desired level.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: June 30, 2020
    Assignee: Outlook Therapeutics, Inc.
    Inventors: Chris Yonan, Christine Caroselli, Wiphusanee Dendamrongvit, Scott Gangloff
  • MODULATION OF CHARGE VARIANTS IN A MONOCLONAL ANTIBODY COMPOSITION
    Publication number: 20180009876
    Abstract: Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to a desired level.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 11, 2018
    Inventors: Chris YONAN, Christine CAROSELLI, Wiphusanee DENDAMRONGVIT, Scott Gangloff